Sign up USA
Proactive Investors - Run By Investors For Investors

AcelRx completes human factors study for painkiller DSUVIA

Study marks last step required before new drug application with FDA
pills
The human factors study was recommended by the FDA

AcelRx Pharmaceuticals Inc (Nasdaq:ACRX), a pharmaceutical group that develops therapies for the treatment of acute pain, has finished its human factors study, which was designed to show the effectiveness of its painkiller DSUVIA’s usage directions.

The completion of the human factors study marks the last step required to prepare AcelRx’s DSUVIA’s new drug application, which is set to be resubmitted to the US Food and Drug Administration in the second quarter of this year.

In morning trade, AcelRx shares rose 4.7% to US$2.35.

“This study was the first of our key 2018 milestones outlined on our year-end earnings call,” said Vince Angotti, chief executive of AcelRx, in a statement. “We remain focused on the achievement of each of these key milestones, which we believe will enable 2018 to be a transformational year for AcelRx.”

DSUVIA consists of 30mcg of sufentanil in small tablets, taken under the tongue, which are delivered via a disposable, pre-filled single dose applicator. The drug is intended to be used to manage acute pain in emergency medicine, outpatient surgery and surgeries when only a short stay is required.

The completion of the human factors study was recommended by the FDA after AcelRx submitted recommended changes to the directions accompanying DSUVIA.

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

Throne of Glass
April 30 2018
Rowling, Rowling, Rowling ... keep those titles rolling. Mind you, it's not all about Ms Rowling; Sarah J Maas title revenues grew 47% in the first half of the financial year and dieters are gorging on Tom Kerridge's books
Email
Wed
Milan Patel, dotdigital’s chief executive officer said: "This year reflects substantial progress against the company's strategic aims in accelerating our platform capabilities into the omnichannel space, continuing to innovate our product, growing geographically and deepening our relationships with our strategic partners”
Cello
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use